查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1831666

处方药市场，规模，占有率，趋势，产业分析报告:各疾病，各地区，2025年～2034年的市场预测

Prescription Drugs Market Size, Share, Trends, & Industry Analysis Report By Ailment (Alzheimer's, Parkinson's, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder), and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，预计到 2034 年，处方药市场规模将达到 2.26 兆美元。本报告深入分析了当前的市场动态，并分析了未来的市场成长。

处方药可以定义为受监管的药物，需要获得医疗保健专业人员的批准才能确保安全有效使用。由于个人化医疗日益受到重视，该市场正在蓬勃发展，个人化医疗正在彻底改变治疗设计和处方。处方药正在摆脱 "一刀切" 的模式，透过根据基因、生活方式和临床因素量身定制治疗方案，更精准地针对特定疾病。这种转变提高了治疗效果，降低了副作用风险，反映了现代医疗保健实践的变化。

数位健康技术与药物开发和病患管理的融合进一步推动了处方药市场的发展。人工智慧、数据分析和互联健康平台的使用正在简化药物研发、临床试验和治疗依从性监测。这些进步提高了整个价值链的效率，同时使患者能够更有效地管理治疗。这些趋势，加上科学创新和技术进步，正在改善患者的治疗效果并重塑处方药市场。

处方药市场报告重点

按疾病类别划分，阿兹海默症预计将在2024年创造最高收入，这得益于老龄化社会中认知能力下降的日益普遍以及对长期治疗方案的需求。

预计北美将在2024年以49.57%的占有率占全球市场的主导地位，这得益于先进的医疗基础设施、新疗法的高采用率以及对药物研发的强劲投资。

预计亚太地区将实现最快的成长，这得益于医疗保健支出的增加、处方药可及性的改善以及注重健康的中产阶级的不断壮大。

全球主要市场参与者包括艾伯维公司 (AbbVie, Inc.)、阿斯特捷利康公司 (AstraZeneca)、百时美施贵宝公司 (Bristol-Myers Squibb Company)、罗氏公司 (F. Hoffmann-La Roche Ltd)、葛兰素史克公司 (Glaxo Services,.Kline plc.)、强生公司 (Johnson), Johnson. Inc.)、诺华公司 (Novartis AG)、辉瑞公司 (Pfizer, Inc.) 和赛诺菲公司 (Sanofi)。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球处方药市场洞察

  • 市场概述
  • 处方药市场动态
    • 促进因素和机会
      • 人口老化
      • 慢性病盛行率上升
    • 高昂的费用和有限的报销
      • 资料隐私风险
  • PESTEL 分析
  • 处方药市场趋势
  • 价值链分析

第5章 全球处方药市场:各疾病

  • 主要调查结果
  • 简介
  • 阿兹海默症
  • 帕金森氏症
  • 偏头痛
  • 慢性疼痛
  • 睡眠障碍
  • 重度忧郁症

第6章 全球处方药市场:各地区

  • 主要调查结果
  • 简介
    • 处方药市场评估:地区，2020～2034年
  • 北美
    • 北美:各疾病，2020～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各疾病，2020～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各疾病，2020～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:各疾病，2020～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:各疾病，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第7章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第8章 企业简介

  • AbbVie, Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
Product Code: PM6345

The prescription drugs market size is expected to reach USD 2.26 trillion by 2034, according to a new study by Polaris Market Research. The report "Prescription Drugs Market Share, Size, Trends, Industry Analysis Report: By Ailment (Alzheimer's, Parkinson's, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder), and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prescription drugs can be defined as regulated medications that require authorization from healthcare professionals to ensure safe and effective use. This market is experiencing growth due to the increasing focus on personalized medicine, which is revolutionizing the design and prescription of treatments. Prescription drugs are moving beyond a "one-size-fits-all" approach and becoming more precise in targeting diseases by tailoring therapies based on genetic, lifestyle, and clinical factors. This transition enhances treatment effectiveness and also reduces the risk of adverse effects, reflecting a shift in modern healthcare practices.

The prescription drugs market is further driven by the integration of digital health technologies into drug development and patient management. The use of artificial intelligence, data analytics, and connected health platforms is streamlining drug discovery, clinical trials, and monitoring of treatment adherence. Such advancements are improving efficiency across the value chain while also empowering patients to manage their therapies more effectively. Together, these trends are reshaping the prescription drugs landscape by combining scientific innovation with technological progress to deliver improved patient outcomes.

Prescription Drugs Market Report Highlights

In terms of ailment, the alzheimer's segment generated the highest revenue in 2024, driven by the increasing prevalence of cognitive decline in aging populations and the necessity for long-term treatment solutions.

North America dominated the global market with a 49.57% share in 2024, attributed to its advanced healthcare infrastructure, high adoption of novel therapies, and strong investment in pharmaceutical R&D.

Asia Pacific region is expected to register the fastest growth rate, propelled by increasing healthcare spending, improved access to prescription drugs, and a growing, health-conscious middle class.

A few global key market players include AbbVie, Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; and Sanofi.

Polaris Market Research has segmented the market report on the basis of ailment, and region:

By Ailment Outlook (Revenue, USD Trillion, 2020-2034)

Alzheimer's

Parkinson's

Migraine

Chronic pain

Arthritic Pain

Neuropathic Pain

Cancer Pain

Chronic Back Pain

Post-Operative Pain

Fibromyalgia

Bone Fracture

Muscle Pain

Acute Appendicitis

Sleep disorders

Insomnia

Hypersomnia

Sleep Apnea

Sleep Breathing Disorder

Circadian Rhythm Disorders

Parasomnia

Sleep Movement Disorders

Major Depressive Disorder

By Regional Outlook (Revenue, USD Trillion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prescription Drugs Market Insights

  • 4.1. Prescription Drugs Market - Market Snapshot
  • 4.2. Prescription Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Prevalence of Chronic Diseases
    • 4.2.2. High Cost and Limited Reimbursement
      • 4.2.2.1. Data Privacy Risk
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prescription Drugs Market Trends
  • 4.6. Value Chain Analysis

5. Global Prescription Drugs Market, by Ailment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 5.3. Alzheimer's
    • 5.3.1. Global Prescription Drugs Market, by Alzheimer's, by Region, 2020-2034 (USD Billion)
  • 5.4. Parkinson's
    • 5.4.1. Global Prescription Drugs Market, by Parkinson's, by Region, 2020-2034 (USD Billion)
  • 5.5. Migraine
    • 5.5.1. Global Prescription Drugs Market, by Migraine, by Region, 2020-2034 (USD Billion)
  • 5.6. Chronic pain
    • 5.6.1. Global Prescription Drugs Market, by Chronic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.2. Arthritic Pain
      • 5.6.2.1. Global Prescription Drugs Market, by Arthritic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.3. Neuropathic Pain
      • 5.6.3.1. Global Prescription Drugs Market, by Neuropathic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.4. Cancer Pain
      • 5.6.4.1. Global Prescription Drugs Market, by Cancer Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.5. Chronic Back Pain
      • 5.6.5.1. Global Prescription Drugs Market, by Chronic Back Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.6. Post-Operative Pain
      • 5.6.6.1. Global Prescription Drugs Market, by Post-Operative Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.7. Fibromyalgia
      • 5.6.7.1. Global Prescription Drugs Market, by Fibromyalgia, by Region, 2020-2034 (USD Billion)
    • 5.6.8. Bone Fracture
      • 5.6.8.1. Global Prescription Drugs Market, by Bone Fracture, by Region, 2020-2034 (USD Billion)
    • 5.6.9. Muscle Pain
      • 5.6.9.1. Global Prescription Drugs Market, by Muscle Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.10. Acute Appendicitis
      • 5.6.10.1. Global Prescription Drugs Market, by Acute Appendicitis, by Region, 2020-2034 (USD Billion)
  • 5.7. Sleep Disorders
    • 5.7.1. Global Prescription Drugs Market, by Sleep Disorders Products, by Region, 2020-2034 (USD Billion)
    • 5.7.2. Insomnia
      • 5.7.2.1. Global Prescription Drugs Market, by Insomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.3. Hypersomnia
      • 5.7.3.1. Global Prescription Drugs Market, by Hypersomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.4. Sleep Apnea
      • 5.7.4.1. Global Prescription Drugs Market, by Sleep Apnea, by Region, 2020-2034 (USD Billion)
    • 5.7.5. Sleep Breathing Disorder
      • 5.7.5.1. Global Prescription Drugs Market, by Sleep Breathing Disorder, by Region, 2020-2034 (USD Billion)
    • 5.7.6. Circadian Rhythm Disorders
      • 5.7.6.1. Global Prescription Drugs Market, by Circadian Rhythm Disorders, by Region, 2020-2034 (USD Billion)
    • 5.7.7. Parasomnia
      • 5.7.7.1. Global Prescription Drugs Market, by Parasomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.8. Sleep Movement Disorders
      • 5.7.8.1. Global Prescription Drugs Market, by Sleep Movement Disorders, by Region, 2020-2034 (USD Billion)
  • 5.8. Major Depressive Disorders
    • 5.8.1. Global Prescription Drugs Market, by Major Depressive Disorders, by Region, 2020-2034 (USD Billion)

6. Global Prescription Drugs Market, by Geography

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Prescription Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 6.3. Prescription Drugs Market - North America
    • 6.3.1. North America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.3.2. Prescription Drugs Market - U.S.
      • 6.3.2.1. U.S.: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.3.3. Prescription Drugs Market - Canada
      • 6.3.3.1. Canada: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.4. Prescription Drugs Market - Europe
    • 6.4.1. Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.2. Prescription Drugs Market - UK
      • 6.4.2.1. UK: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.3. Prescription Drugs Market - France
      • 6.4.3.1. France: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.4. Prescription Drugs Market - Germany
      • 6.4.4.1. Germany: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.5. Prescription Drugs Market - Italy
      • 6.4.5.1. Italy: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.6. Prescription Drugs Market - Spain
      • 6.4.6.1. Spain: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.7. Prescription Drugs Market - Netherlands
      • 6.4.7.1. Netherlands: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.8. Prescription Drugs Market - Russia
      • 6.4.8.1. Russia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.9. Prescription Drugs Market - Rest of Europe
      • 6.4.9.1. Rest of Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.5. Prescription Drugs Market - Asia Pacific
    • 6.5.1. Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.2. Prescription Drugs Market - China
      • 6.5.2.1. China: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.3. Prescription Drugs Market - India
      • 6.5.3.1. India: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.4. Prescription Drugs Market - Malaysia
      • 6.5.4.1. Malaysia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.5. Prescription Drugs Market - Japan
      • 6.5.5.1. Japan: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.6. Prescription Drugs Market - Indonesia
      • 6.5.6.1. Indonesia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.7. Prescription Drugs Market - South Korea
      • 6.5.7.1. South Korea: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.8. Prescription Drugs Market - Australia
      • 6.5.8.1. Australia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.9. Prescription Drugs Market - Rest of Asia Pacific
      • 6.5.9.1. Rest of Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.6. Prescription Drugs Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.2. Prescription Drugs Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.3. Prescription Drugs Market - UAE
      • 6.6.3.1. UAE: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.4. Prescription Drugs Market - Israel
      • 6.6.4.1. Israel: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.5. Prescription Drugs Market - South Africa
      • 6.6.5.1. South Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.6. Prescription Drugs Market - Rest of Middle East & Africa
      • 6.6.6.1. Rest of Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.7. Prescription Drugs Market - Latin America
    • 6.7.1. Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.2. Prescription Drugs Market - Mexico
      • 6.7.2.1. Mexico: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.3. Prescription Drugs Market - Brazil
      • 6.7.3.1. Brazil: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.4. Prescription Drugs Market - Argentina
      • 6.7.4.1. Argentina: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.5. Prescription Drugs Market - Rest of Latin America
      • 6.7.5.1. Rest of Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. AbbVie, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. Bristol-Myers Squibb Company
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. F. Hoffmann-La Roche Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. GlaxoSmithKline plc.
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. Johnson & Johnson Services, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. Merck & Co., Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Novartis AG
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Pfizer, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development

List of Tables:

  • Table 1 Global Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 2 North America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 3 U.S.: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 4 Canada: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 5 Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 6 UK: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 7 France: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 8 Germany: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 9 Italy: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 10 Spain: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 11 Netherlands: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 12 Russia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 13 Rest of Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 14 Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 15 China: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 16 India: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 17 Malaysia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 18 Japan: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 19 Indonesia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 20 South Korea: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 21 Australia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 22 Rest of Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 23 Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 24 Saudi Arabia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 25 UAE: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 26 Israel: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 27 South Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 28 Rest of Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 29 Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 30 Mexico: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 31 Brazil: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 32 Argentina: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 33 Rest of Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Prescription Drugs Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Ailment
  • Figure 7. Global Prescription Drugs Market, by Ailment, 2024 & 2034 (USD Billion)